CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
CATCH is an indication-specific diagnostic platform, which drives the implementation of integrative, genomic profiling for metastatic breast cancer into the clinics. The main objective of this approach is to identify biomarkers and drug targets to guide targeted therapeutic interventions. Eligible are all metastatic breast cancer patients (independent of gender), irrespective of molecular subtype. At initial diagnosis of distant metastasis or progress at disease progression, biopsy samples from a prognostic-relevant metastasis are retrieved during standard-of-care procedures for central analyses, together with blood samples. In parallel to all standard-diagnostic measures, genomic and transcriptomic profiling is conducted to infer the underlying biology of the disease and identify patients who might profit from biomarker-guided interventions in clinical trials. Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data). In summary, the overarching goal is to generate a precision oncology platform to i) identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) couple the observational, diagnostic registry platform to an increasing number of independent, biomarker-stratified clinical therapy trials (CATCH-GUIDE).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety i mężczyźni z rakiem piersi w wieku 18 lat lub starsi (albo opiekun prawny wyraził zgodę)
- •Pacjenci z zaawansowanym rakiem piersi lub rakiem rozsianych ognisk
- •Pacjenci, którzy wyrazili zgodę i byli w stanie podpisać formularz świadomej zgody
✗ Disqualifies
- •Wczesny stadium raka piersi
- •Niemożliwość pobrania próbki tkanki ze względu na lokalizację guza lub stan zdrowia pacjenta
- •Poważne problemy zdrowotne lub psychiczne utrudniające współpracę z pacjentem
Simplified criteria — AI translation
Trial details
- Minimum age
- 14 Years
- Maximum age
- 100 Years
- Last updated (source)
- January 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (12)
University Hospital Augsburg
Augsburg, Germany
Charité
Berlin, Germany
University Hospital Köln
Cologne, Germany
Medical Faculty and University Hospital Carl Gustav Carus
Dresden, Germany
University Hospital Erlangen
Erlangen, Germany
University Hospital Essen
Essen, Germany
National Center for Tumor Diseases
Heidelberg, Germany
Caritas Hospital St. Josef
Regensburg, Germany
Robert-Bosch-Krankenhaus Stuttgart
Stuttgart, Germany
University Hospital Tübingen
Tübingen, Germany
University Hospital Ulm
Ulm, Germany
University Hospital Würzburg
Würzburg, Germany
Trial contact
Andreas Schneeweiss, MD
Peter Lichter, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.